ES2170853T3 - Nanosferas que comprenden un polisacarido biocompatible. - Google Patents

Nanosferas que comprenden un polisacarido biocompatible.

Info

Publication number
ES2170853T3
ES2170853T3 ES96909138T ES96909138T ES2170853T3 ES 2170853 T3 ES2170853 T3 ES 2170853T3 ES 96909138 T ES96909138 T ES 96909138T ES 96909138 T ES96909138 T ES 96909138T ES 2170853 T3 ES2170853 T3 ES 2170853T3
Authority
ES
Spain
Prior art keywords
microspheres
preparation
biocompatible
polisacaride
nanospheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909138T
Other languages
English (en)
Inventor
Paolo Pallado
Luca Benedetti
Lanfranco Callegaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anika Therapeutics SRL
Original Assignee
Fidia Advanced Biopolymers SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT95PD000065A external-priority patent/IT1281857B1/it
Priority claimed from IT96PD000021 external-priority patent/IT1287194B1/it
Application filed by Fidia Advanced Biopolymers SRL filed Critical Fidia Advanced Biopolymers SRL
Application granted granted Critical
Publication of ES2170853T3 publication Critical patent/ES2170853T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)

Abstract

SE PREPARAN MICROESFERAS, QUE POSEEN UN TAMAÑO INFERIOR A 1 {MI} Y QUE COMPRENDEN UN POLIMERO DE POLISACARIDO BIOCOMPATIBLE, MEDIANTE UN PROCESO QUE COMPRENDE LA PRECIPITACION DEL POLIMERO INDUCIDA MEDIANTE UN ANTISOLVENTE SUPERCRITICO (SAS). ESTAS MICROSFERAS SE EMPLEAN COMO AGENTES DE VEHICULACION O VEHICULOS EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS ADMINISTRABLES MEDIANTE RUTA ORAL, NASAL, PULMONAR, VAGINAL O RECTAL. ESTAS MICROESFERAS PUEDEN SER UTILIZADAS TAMBIEN CON VENTAJA COMO AGENTES DE VEHICULACION O VEHICULOS EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE ENFERMEDADES HUMANAS ASOCIADAS CON DEFECTOS GENICOS, PARA LA PREPARACION DE ELEMENTOS DE DIAGNOSTICO Y EN LA INDUSTRIA AGROALIMENTARIA.
ES96909138T 1995-03-28 1996-03-26 Nanosferas que comprenden un polisacarido biocompatible. Expired - Lifetime ES2170853T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT95PD000065A IT1281857B1 (it) 1995-03-28 1995-03-28 Processo per la preparazione di microsfere mediante l'impiego di fluidi supercritici.
IT96PD000021 IT1287194B1 (it) 1996-02-05 1996-02-05 Processo per la preparazione di microsfere mediante l'impiego di fluidi supercritici
PCT/EP1996/001354 WO1996029998A1 (en) 1995-03-28 1996-03-26 Nanospheres comprising a biocompatible polysaccharide
US08/938,288 US6214384B1 (en) 1995-03-28 1997-09-26 Nanosheres comprising a biocompatible polysaccharide

Publications (1)

Publication Number Publication Date
ES2170853T3 true ES2170853T3 (es) 2002-08-16

Family

ID=27274135

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909138T Expired - Lifetime ES2170853T3 (es) 1995-03-28 1996-03-26 Nanosferas que comprenden un polisacarido biocompatible.

Country Status (8)

Country Link
US (2) US6214384B1 (es)
EP (1) EP0817620B1 (es)
AT (1) ATE212545T1 (es)
AU (1) AU695207B2 (es)
CA (1) CA2216919C (es)
DE (1) DE69618938T2 (es)
ES (1) ES2170853T3 (es)
WO (1) WO1996029998A1 (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0965336A1 (en) 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
DE19711393C1 (de) * 1997-03-19 1998-08-13 Fraunhofer Ges Forschung Verfahren zum Mikroverkapseln von Partikeln
JP2002506436A (ja) * 1997-06-13 2002-02-26 ザ ジョンズ ホプキンス ユニバーシティー 治療用ナノスフェア
US6045815A (en) 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
CA2324254C (en) * 1998-03-18 2005-01-04 University Technology Corporation Sustained-release composition including amorphous polymer
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6824793B1 (en) 1998-06-01 2004-11-30 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
WO1999065531A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
SE9804000D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New composition of matter
EP1154793B1 (en) 1999-02-26 2010-09-15 Novartis Vaccines and Diagnostics, Inc. Use of bioadhesives and adjuvants for the mucosal delivery of antigens
IT1306644B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
IT1306643B1 (it) * 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
FR2797398B1 (fr) * 1999-08-11 2002-10-18 Mainelab Microparticules pour administration pulmonaire
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
GB9927011D0 (en) * 1999-11-16 2000-01-12 Advanced Phytonics Ltd Method for the production of particles
CH694686A5 (it) * 2000-03-04 2005-06-15 Eco2 Sa Prodotto di micronizzazione di sostanze farmaceutiche.
WO2001068158A1 (en) 2000-03-15 2001-09-20 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
IT1318404B1 (it) * 2000-03-17 2003-08-25 Eurand Int Processo per la preparazione di formulazioni a rilascio accelerato conimpiego di fluidi compressi.
FR2815540B1 (fr) † 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7094369B2 (en) * 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7131997B2 (en) * 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7053134B2 (en) * 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US7449236B2 (en) * 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US7588825B2 (en) * 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7883490B2 (en) * 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US6931888B2 (en) * 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US9066912B2 (en) * 2003-11-17 2015-06-30 Ethicon, Inc. Drug-enhanced adhesion prevention
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US7736671B2 (en) * 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US20050238870A1 (en) * 2004-04-22 2005-10-27 Marcia Buiser Embolization
WO2005107817A2 (en) 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US7311861B2 (en) * 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
WO2007013881A2 (en) 2004-09-27 2007-02-01 Auburn University Selection and deposition of nanoparticles using co2-expanded liquids
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
US7858183B2 (en) * 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) * 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) * 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
JP2008543842A (ja) * 2005-06-14 2008-12-04 バクスター インターナショナル インコーポレイテッド 薬物−薬物相互作用を最小にするための薬学的処方物
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20070004973A1 (en) * 2005-06-15 2007-01-04 Tan Sharon M L Tissue treatment methods
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
US9463426B2 (en) * 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
AU2006315177A1 (en) * 2005-11-15 2007-05-24 Baxter Healthcare S.A. Compositions of lipoxygenase inhibitors
US20070142560A1 (en) * 2005-12-21 2007-06-21 Young-Ho Song Block copolymer particles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US7501179B2 (en) * 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
CA2648291A1 (en) * 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
RU2010102865A (ru) * 2007-07-24 2011-08-27 НексБио, Инк. (US) Технология изготовления микрочастиц
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
US8215489B1 (en) 2008-10-31 2012-07-10 Auburn University Method and apparatus for physical separation of different sized nanostructures
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
ITRM20110008A1 (it) * 2011-01-12 2012-07-13 Alfonso Barbarisi Procedimento per la partecipazione di nanoparticelle reticolate a base di estere benzilico dell'acido ialuronico da utilizzare come vettori per il rilascio controllato di principi attivi
WO2012119980A1 (en) * 2011-03-04 2012-09-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Particles containing a growth factor, and uses thereof
TWI419701B (zh) * 2011-11-08 2013-12-21 包覆生長因子之多醣體微粒子
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US9598503B2 (en) 2012-04-18 2017-03-21 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
JP2015527310A (ja) 2012-06-28 2015-09-17 アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. 下気道および中枢気道への送達用微粒子製剤ならびに製造方法
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
EP3807644A4 (en) 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
EP4069726A4 (en) 2019-12-04 2024-03-20 The Scripps Research Institute GLP2 RECEPTOR AGONISTS AND METHOD OF USE
US20250197525A1 (en) 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
CA3248580A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185625A (en) * 1961-11-08 1965-05-25 Brown Ethan Allan Injectionable substances
EP0093757A1 (en) * 1981-11-12 1983-11-16 Ulf SCHRÖDER Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
DE68907062T2 (de) * 1988-10-05 1993-10-07 Upjohn Co Feinverteiltes feste kristalline pulver durch niederschlag in einem anti-lösungsmittel.
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
ATE178789T1 (de) * 1994-02-21 1999-04-15 Takeda Chemical Industries Ltd Polyester matrix für eine pharmazeutische zusammensetzung mit verzögerter freigabe
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles

Also Published As

Publication number Publication date
DE69618938T2 (de) 2002-10-31
CA2216919C (en) 2007-09-18
EP0817620A1 (en) 1998-01-14
US6541035B1 (en) 2003-04-01
WO1996029998A1 (en) 1996-10-03
DE69618938D1 (de) 2002-03-14
AU5274996A (en) 1996-10-16
EP0817620B1 (en) 2002-01-30
CA2216919A1 (en) 1996-10-03
AU695207B2 (en) 1998-08-06
US6214384B1 (en) 2001-04-10
ATE212545T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
ATE212545T1 (de) Nanosphären mit einem biokompatiblen polysaccharid
DE69021214D1 (de) Orale zusammensetzung für die behandlung intestinaler entzündlicher krankheiten.
DE69429078D1 (de) Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ATE199060T1 (de) Tierarzneimittel, das einen protonenpumpeninhibitor enthält
NO950784L (no) Fettsyrederivater
BR0015506A (pt) Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
NO922936L (no) Fremstilling av fettsyremedikamenter
PT862480E (pt) Sistema ou aparelho para tratamento do ureter ou da juncao do bacinete com o ureter
ES2194727T3 (es) Estructuras tridimensionales que contienen derivados del acido hialuronico obtenidos por la tecnica del antidisolvente supercritico.
GR3031250T3 (en) Methods of diagnosing and treating preeclampsia
DE69033970D1 (de) Huperzin a analoge verbindungen
ITRM920900A0 (it) Formulazione proteica coadiuvante nella prevenzione e cura delle parodontiti e di altre patologie batteriche del cavo orale.
Taysi et al. A new syndrome of proximal deletion of the long arm of chromosome 1: 1q21–23→ 1q25
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ES2110258T3 (es) Derivados de 1,3,5(10)-estratrieno activos por via oral.
DE69012386D1 (de) Impfstoff und Diagnostikum für den Schweine-Cholera-Virus.
DE69003960D1 (de) Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten.
CA2369275A1 (en) Process for the preparation of autocrosslinked compounds of hyaluronic acid and the derivatives thereof by the supercritical antisolvent technique
DE3878154D1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
NO960347D0 (no) Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF
NO911460D0 (no) Fremgangsmaate og apparat for redusere konsentrasjonen av hydroxylioner i vandige opploesninger av hydroxyl- og perhydroxylioner.
HUP0102116A2 (hu) Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 817620

Country of ref document: ES